Drug Profile
ATX 101 - APIM Therapeutics
Alternative Names: ATX-101Latest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator APIM Therapeutics; Norwegian university of science and technology
- Developer APIM Therapeutics; Columbia University
- Class Antineoplastics; Peptides
- Mechanism of Action Protein interaction domain and motif inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Leiomyosarcoma; Liposarcoma
- Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase I Solid tumours
- No development reported Bladder cancer; Cancer; Multiple myeloma
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Bladder-cancer(Combination therapy) in Norway (Topical)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Bladder-cancer(Combination therapy, Late-stage disease) in Norway (Parenteral)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in Norway (Parenteral)